The role of EBUS-TBNA in genetic phenotype determination at adenocarcinoma cases

B. Caglayan (Istanbul, Turkey), S. COMERT (Istanbul, Turkey), S. I?liaz (Istanbul, Turkey), Ö. Zengin (Istanbul, Turkey), P. Bulutay (Istanbul, Turkey), N. Barisik (Istanbul, Turkey)

Source: International Congress 2018 – Lung cancer: new tools for diagnosis and patient assessment
Session: Lung cancer: new tools for diagnosis and patient assessment
Session type: Thematic Poster
Number: 2777
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
B. Caglayan (Istanbul, Turkey), S. COMERT (Istanbul, Turkey), S. I?liaz (Istanbul, Turkey), Ö. Zengin (Istanbul, Turkey), P. Bulutay (Istanbul, Turkey), N. Barisik (Istanbul, Turkey). The role of EBUS-TBNA in genetic phenotype determination at adenocarcinoma cases. 2777

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The effect of 19G EBUS-TBNA biopsies on characterisation of malignant and benign disease
Source: International Congress 2017 – EBUS
Year: 2017

Aberrant methylation in lung cancer identified by EBUS-TBNA as a marker of advanced staging
Source: Annual Congress 2012 - Progress in endoscopy for lung cancer
Year: 2012

The role of radiology in lung adenocarcinoma classification
Source: Annual Congress 2009 - The new ERS/ATS/IASLC classification of lung adenocarcinoma: practice update
Year: 2009


Adequacy of EBUS-TBNA specimens for molecular testing in lung adenocarcinoma
Source: International Congress 2017 – EBUS
Year: 2017


The role of molecular pathology in diagnosis and treatment of lung cancer
Source: Annual Congress 2007 - PG9 - Molecular pathology and genetics in lung diseases
Year: 2007



Interobserver agreement in determining non-small cell lung cancer subtype in specimens acquired by EBUS-TBNA},
Source: Eur Respir J 2012; 40: 699-705
Year: 2012



Additional value of histological specimens obtained by 19G TBNA needle in diagnosing malignant mediastinal lesions
Source: Annual Congress 2007 - Bronchoscopic staging modalities in lung cancer
Year: 2007



Evaluating the role of muc4 expression in the differential diagnosis of mesothelioma and adenocarcinoma of the lung
Source: Eur Respir J 2006; 28: Suppl. 50, 81s
Year: 2006

The role of P53 tumor suppressor gene mutations in early diagnosis of lung cancer among patients with solitary pulmonary nodule
Source: Annual Congress 2009 - Pathogenesis of lung cancer
Year: 2009

The role of fibrobronhoscopy in endobronchial metastasis diagnosis
Source: Eur Respir J 2007; 30: Suppl. 51, 100s
Year: 2007

The role of VATS in the staging of non small cell lung cancer
Source: Annual Congress 2011 - General thoracic surgery I
Year: 2011

The role of transbronchial needle aspiration in diagnosis and staging of the patients with lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 514s
Year: 2006

Shox2, a biomarker for confirming malignancy in bronchial lavage from patients with suspected lung cancer and inconclusive cytology
Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer
Year: 2009


Detection of aberrant methylation of p16(INK4a) and MGMT in endobronchial specimens increases the diagnostic yield in cases of suspected peripheral lung carcinomas
Source: Eur Respir J 2002; 20: Suppl. 38, 2s
Year: 2002

Accuracy of cell typing in nonsmall cell lung cancer by EBUS/EUS–FNA cytological samples
Source: Eur Respir J 2011; 38: 911-917
Year: 2011



Evaluation of the role of bronchoscopy in the diagnosis of lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 84s
Year: 2006

The role of endobronchial ultrasound in staging of lung cancer
Source: Annual Congress 2004 - PG2 - Lung Cancer: bronchoscopic tools in diagnosis, staging, and treatment
Year: 2004


EBUS-TBNA for the diagnosis of intrathoracic lymphadenopathy in patients with previously diagnosed breast carcinoma
Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma
Year: 2018


The value of immunohistochemical markers in the differential diagnosis of adenocarcinomas
Source: Annual Congress 2011 - Quality management for lung cancer patients
Year: 2011